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1. Introduction
The word ‘psoriasis’, is derived from the Greek word “psora” meaning “itch” or “scurf” or
“rash”, although most patients suffering from the condition do not complain of itching. It
has been known since ancient times and was originally considered a type of leprosy. For
quite some time now, it is one of the most common human skin diseases. Up to a few deca‐
des back, psoriasis was considered to be a chronic inflammatory dermatosis with albeit, ge‐
netic factors involved in the pathogenesis.
It is now considered a multifactorial disorder that has several factors like genetic predisposi‐
tion, environmental, immunologically mediated inflammation and several modifying factors
including obesity, trauma, infection and a possible deficiency of the active forms of vitamin D3.
Different subsets of T lymphocytes, antigen presenting cells (APC's), keratinocytes, Langer‐
hans' cells, macrophages, natural killer cells, an array of Th1 type cytokines, certain growth fac‐
tors like vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) etc are
involved [1].
Psoriasis was long-considered either a disorder of keratinocyte growth or a chronic inflam‐
mation. However, advancement in immunologic techniques and in genetic analyses over the
past four decades have resulted in a reappraisal of the pathophysiology involved. Some con‐
sider psoriasis as an organ-specific autoimmune disease that is triggered by an activated cel‐
lular immune system and is similar to other immune-mediated diseases such as Crohn's
disease, rheumatoid arthritis, multiple sclerosis and juvenile-onset diabetes. All of these fit
the definition of an autoimmune disease as "a clinical syndrome caused by the activation of
T cells and B cells, or both, in the absence of an ongoing infection or other discernable cause"
[2]. From the many factors postulated to be involved in the pathophysiology of psoriasis and
psoriatic arthritis, it is obvious that the mechanism leading to the development of the sym‐
metrically present discoid plaques with silvery scales, is still not understood clearly. In spite
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of the plethora of research studies into its pathogenesis, psoriasis still poses a challenge to
the scientific community to, once and for all, establish how and why it occurs and conse‐
quently to develop the magic drug to treat it.
2. Role of genetic factors
The idea that psoriasis has a genetic component has been there for over a 100 years but it was
Lomholt’s classic epidemiologic study in 1963 that really established the genetic component in
psoriasis. He investigated more than 11,000 of the 30,000 inhabitants of the Faroe islands and
studied psoriatic patients and their unaffected relatives. He found a clear genetic basis as the
incidence of psoriasis was much greater amongst first- and second degree relatives of patients
with psoriasis. Lomholt however, was unable to establish a particular inheritance pattern [3].
Further studies performed in Sweden and later in Germany supported Lomholt’s data.
Hellgren published extensive data showing the prevalence of psoriasis to be 7.8% in first de‐
gree relatives compared with a prevalence of 3.14% in matched controls, and 1.97% in the
overall population [4].
3. Racial & geographic variations
Although, psoriasis occurs worldwide, its prevalence is highest in Scandinavian countries and
Northern Europe (3%); in contrast, its prevalence in North America and the UK its prevalence
is ∼2%, while in Japan its prevalence is ∼0.2% of the population. Far more interesting is the fact
that it is rare in Native American Indians although it is much more prevalent n the USA where 3
million office visits for psoriasis are made each year, costing over $3 billion [5]. It contributes to
approximately 1-5% of all skin disorders in Saudi Arabia [6].
3.1. Establishing a genetic component
Over the past two decades or so, cumulative evidence establishing a substantive role for ge‐
netic factors in respect to disease susceptibility and expression is based on family based in‐
vestigations; population based epidemiological studies, association studies with human
leucocyte antigens (HLAs), genome-wide linkage scans, and candidate gene studies within
and outside the major histocompatibility complex (MHC) region [7 & 8].
3.2. Concordance
There is marked variation in concordance for monozygotic twins in various studies: 35-73%
and the concordance never approaching 100% raises the possibility that genetic factor proba‐
bly act with environmental ones = 12-14 Fitz. The concordance of psoriasis in monozygotic
twins approached 65–72%, versus 15–30% in dizygotic twins. Determination of concordance
in older twin pairs from a national twin registry in Denmark revealed nearly 90–100% herit‐
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ability [5]. However, in an Australian study the monozygotic twin concordance rate was
found to be considerably lower (35% for monozygotic twins and 12% for dizygotic twins),
giving an estimated heritability of 80% [9].
3.3. Inheritance pattern
Despite all the work on psoriasis, the inheritance pattern has not been ascertained and psor‐
iasis has by various authors, been considered a single gene disorder with an autosomal
dominant inheritance with its variable expressivity and reduced penetrance or an autosomal
recessive disorder because of multiple affected individuals in a family. Patients with more
dominance of genetic factors have more severe disease and in a younger age group. The risk
for a person of developing psoriasis is 41% if both parents affected; 14% if 1 parent is affect‐
ed, 6% if one sibling is affected and only 2% when no parent or sibling is affected [10].
However, Swanbeck et al presented empirical data that may be of more relevance for genet‐
ic counseling. After assessing over 3000 families in which one or both parents had psoriasis,
the calculated lifetime risk of getting psoriasis if no parent, one parent, or both parents have
psoriasis was found to be 0.04, 0.28, and 0.65, respectively. If there was already one affected
child in the family, the corresponding risks were 0.24, 0.51, and 0.83, respectively [11].
Possession of certain HLA class I antigens, particularly HLA-Cw6, is associated with an ear‐
lier age of onset and with a positive family history. This finding led to the proposal that two
different forms of psoriasis exist: type I psoriasis, with age of onset before 40 years and
HLA-associated, and type II, with age of onset after 40 years and lacking HLA associations,
although many patients do not fit into this classification. There is no evidence that type I
and type II psoriasis respond differently to different therapies. So far, between 10 and 20
chromosome regions have been proposed to harbour psoriasis genes but less than a handful
of genes have been identified. This is due, in part, to their low-risk effects and the limitations
in the number of patients and families that have been studied. One locus consistently identi‐
fied in studies of psoriasis is the class I region of the major histocompatibility locus antigen
cluster. However, it’s low penetrance — about 10% — indicates that other genetic and envi‐
ronmental factors are also involved. The identity of psoriasis susceptibility 1 (PSORS1) re‐
mains controversial. Although its association with human leukocyte antigen (HLA) Cw6
and psoriasis was reported more than 25 years age, the extensive linkage disequilibrium
across the class I region and its complex evolutionary history has made identification of the
susceptibility variant(s) very difficult. Genes within this region lying about 160 kilobases te‐
lomeric to HLA-C, such as corneodesmosin (CDSN) and the α-helical coiled-coil rod (HCR),
have been proposed as contenders. A consensus is now beginning to emerge that supports
the location of PSORS1 as being closer to the region harboring HLA-C/HLA-B and exclud‐
ing CDSN and HCR. However, whether PSORS1 is a classical MHC allele, or a regulatory
variant within this region, has not yet been agreed upon. Other predisposing polygenes
might affect the immune system or be involved in keratinocyte differentiation. Common
variants in the SLC9A3R1/NAT9 region and loss of a potential RUNX binding site have been
described that could potentially affect regulation of the immune synapse [12].PSORS1 is lo‐
cated in the major histocompatibility complex (MHC, chromosome 6p21.3), home of the
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HLA) genes.17 Multiple HLA alleles have been associated with psoriasis, particularly HLA-
B13, HLA-B37, HLA-B46, HLA-B57, HLA-Cw1, HLA-Cw6, HLA-DR7, and HLA-DQ9.10
Many of these alleles are in linkage disequilibrium with HLA-Cw6 (i.e., found together on
the same chromosome more often than would be predicted by chance). HLA-Cw6 has con‐
sistently demonstrated the highest relative risk for psoriasis in Caucasian populations [13].
4. Immunological factors in psoriasis
Both innate and acquired immune changes are thought to be responsible for the develop‐
ment of psoriatic plaques. Different types of helper T subsets, dendritic cells, plasmacytoid
dendritic cells as well as Langerhans cells have been found to play a role in psoriasis. Re‐
search had already suggested the role of T cells in psoriasis. Further studies led to the suc‐
cessful use of T-cell immunosuppressant cyclosporin A in the treatment of psoriasis The
concept that T cell activation is a key event in psoriasis was further strengthened with the
successful use of anti-T cell specific drugs in the form of anti-CD3 and -CD4 monoclonal an‐
tibodies in treatment. There is also the possibility that psoriasis may be an organ-specific au‐
toimmune disease with similarities to rheumatoid arthritis and multiple sclerosis and the
recent use of so-called “etio-pathogenetic” drugs like methotrexate, and alefacept suggests
autoimmunity as a major factor in pathogenesis. [14].
5. Histologic features of psoriasis and their Immunological basis
Light Microscopic features of psoriasis include three predominant groups of changes: i) epi‐
dermal hyperplasia ii) inflammatory infiltrate and iii) vascular changes. All of these changes
must be explained satisfactorily by any hypothesis, to withstand a critical scrutiny. The epi‐
dermal changes include keratinocyte hyperplasia, an attenuated or absent granular cell layer
and impaired keratinocyte differentiation and maturation. The combination of these epider‐
mal changes leads to the thick scaly plaques characteristic of psoriasis [15]. The inflammato‐
ry infiltrate in the dermis is seen to invade the epidermis (exocytosis) and is mainly
composed of Th1 helper T cells as well as the cytotoxic CD8+ cells. In addition there is an
infiltration of neutrophils that go on to form the diagnostic histologic features spongiform
pustule of Kogoj and Munro microabscess. The third change is vascular and consists of in‐
creased number of the vessels in the superficial vascular plexus with tortuosity of vessels
and most interestingly venulization of the capillary network so that the vessels become HEV
(High Endothelial Venules) [16].
The presence of T cells in the inflammatory infiltrate in psoriatic plaques obviously indicat‐
ed an immune-mediated or an autoimmune basis for the pathogenesis of psoriasis. The evi‐
dence of an immune basis comes from research in the laboratory with experimental animals
as well as from clinical research and particularly the significant regression of the disease
with the use immunosuppressive agents like cyclosporine which act against T cells.
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6. Mouse models of psoriasis and the immune basis of the disease
There is no animal model where psoriatic lesions may be produced de novo. Initially
humanized mouse models in which psoriatic skin was xenografted onto immunodeficient
mice was used as a means to study the immune pathways leading to the development and
resolution of psoriatic lesions. When non-lesional (normal-looking) skin from psoriatic pa‐
tients was injected with superantigen-activated leukocytes and subsequently grafted onto
these mice, there was development of new lesions on the transplanted skin. This provided
strong evidence that T cells play a key role in the pathology of the disease. Later, a new
model of xenotransplantation was developed. This entailed non-lesional skin from psoriatic
patients being engrafted onto AGR129 mice (lacking T and B cells and with severely im‐
paired NK cell responses). It was seen that the non-lesional skin grafts transplanted onto
AGR129 mice spontaneously converted to lesional skin, suggesting that all of the elements
required for the development of psoriasis lesions are present in non-lesional skin. This con‐
version was associated with enhanced proliferation of T cells that are resident in non-lesion‐
al skin and increased TNF-α production. All this argued in favor of a dominant role of
cytokines and T cells in the pathogenesis indicating an immune or autoimmune basis [17].
Valdmarson et al discovered that an early event in the evolving lesions of guttate psoriasis
was an intrepidermal influx of activated T cells that were HLA- DR+, CD4+, while on the
other hand, resolving plaques of psoriasis showed a reduced intraepidermal infiltration [18].
However, evidence was produced by other researchers showing that CD8+ T cells were pre‐
dominant in psoriatic epidermis and that the decrease in the number of these cells was more
closely related to resolution of the plaques following treatment. But regardless of the pheno‐
type of these T cells, it was agreed that they were activated and that they were HLA- DR+,
expressed the IL-2 receptor CD25 and also secreted cytokines IL-2 and γ-IFN both of which
are involved in the activation of T cells [19]. It was also deduced from the presence of acti‐
vated and proliferating dermal dendritic antigen-presenting cells the presence of activated
and proliferating memory T cells, that the signals for these changes were derived from the
skin itself [20].
It was also noted by different researchers that the T cells in present in psoriatic plaques of
different patterns of psoriasis based on two different groups of cytokines secreted. Mossman
for example found that a Th1 profile is indicated by a predominance of IL-2, IL-12 and γ-
interferon while a Th2 profile is indicated by the predominance of IL-4, IL-5 and IL-10 [21].
7. Innate immunity in psoriasis
The role of the innate immune system in psoriasis is increasingly seen as important. Neutro‐
phils are found in the stratum corneum of psoriatic skin [22]. Since neutrophils have a short
life span (about 3 days), their persistent presence in the epidermis suggests that they are
continually recruited. Dendritic cells (DCs) are increased in psoriatic lesions and also appear
to play their part in the T-cell response [23 & 24].
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Subsets of DCs not usually found in the skin are also observed to be present in psoriatic skin
lesions. Plasmacytoid DCs are potent producers of IFN-α, which is thought to be a key cyto‐
kine in triggering lesion development, and myeloid DCs, with the ability to secrete TNF-α
and inducible nitric oxide synthase, have been also been observed in psoriatic skin. There
are increased numbers of mature and activated DCs in psoriatic lesions implying that these
cells may be stimulating other aspects of the immune response. Innate immunity is associat‐
ed with the production of proinflammatory or primary cytokines. The most important of
them are IL-1α and TNF-α. The role of IL-1α is unclear as detection in psoriasis lesions has
given conflicting results. TNF-α is increased in lesional skin of psoriasis patients and in
synovium of patients with psoriatic arthritis [25].
8. Natural Killer (NK) cells and psoriasis
NK cells are lymphocytes that are generally considered to be part of the innate immune sys‐
tem. They are best known for their ability to kill virally infected and cancer cells; however,
they also produce a range of cytokines including IFN-γ, TNF-α, and TGF-β. They can be de‐
fined phenotypically by the presence of particular surface antigens: either NKp46 or
CD56+CD3−cells. While the role of NK cells in psoriasis still remains relatively unstudied,
there is mounting evidence that these cells may contribute to disease. Ottaviani et al. found
that the inflammatory infiltrate into psoriatic skin consisted of 5–8% cells that expressed the
NK cell phenotype of CD56+CD3−. Most of these were of the CD56bright subset of NK cells.
Thought to represent more immature cells, CD56bright cells are less cytotoxic and more profi‐
cient at cytokine secretion compared to CD56dim NK cells. The cells present in the infiltrate
found by Ottaviani et al. also expressed the activation antigen, CD69, and produced large
quantities of IFN-γ in vitro in response to IL-2 stimulation. Supernatants from these IL2-
stimulated NK cells induced activation of keratinocytes causing upregulation of MHC class
I molecules and induction of the expression of ICAM1 and HLA-DR receptors. The keratino‐
cytes were also observed to secrete chemokines that are known to attract NK cells (CXCL10,
CCL5, and CCL20) thereby providing a mechanism of NK cell recruitment to the skin [26].
More weight is added to the possibility of a dysregulated immune system playing a role in
psoriasis by the impressively good response following treatment with TNF-α neutralizing
modalities. For example, one course of infliximab (Remicade®) results in an impressive Psor‐
iasis Activity and Severity Index (PASI) 75 of 80%, meaning that at least 80% of patients
have a decrease of at least 75% of their psoriasis skin symptoms [27]
9. Neutrophils and psoriasis
Although psoriasis is a chronic disease, the skin lesions often contain groups of neutrophils
within small spongiotic foci in the superficial part of the stratum spinosum of the epidermis
as well as intermittently within the stratum corneum. Thus, there is an element of acute in‐
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flammation changes in the disease which often persists for decades. Thought to be recruited
and subsequently activated by a high gradient of chemotactic factors like chemokines, IL-8
and Gro-a released by the stimulated keratinocytes, and particularly C5a/C5a des-arg pro‐
duced via the alternative complement pathway. Initially, the presence of neutrophils in
psoriatic epidermis was considered a secondary and rather passive phenomenon. However,
Terui et al proposed “a neutrophil-associated inflammation-boosting loop” and suggested
that this may well explain the localized ‘‘acute’’ inflammatory changes scattered over the
‘’chronic’’ psoriatic plaques as well as in the acutely inflamed lesions of pustular psoriasis.
They proposed that these neutrophils may actively increase the activation of T cells and that
the activated T cells in turn release cytokines to stimulate epidermal keratinocytes to pro‐
duce IL-8 and C3 that facilitates complement activation as well as PMN accumulation. The
neutrophils forming the intra-corneal Munro microabscess may also influence keratinocytes
to induce disturbances of epidermal keratinization and underlying hyperproliferation. They
also express HLA-DR under the influence of IFN-g and GM-CSF in turn to potentiate T cells.
Thus, PMNs infiltrating into the lesional skin may play a pivotal role in eliciting the acute
inflammatory and hyperplastic responses in classic psoriatic plaques [28].
10. Acquired immunity & psoriasis
In contrast to neutrophils which are not persistently present in all psoriatic lesions, in‐
creased numbers of T lymphocytes are a highly consistent finding in psoriasis biopsies. With
immunohistochemical staining, T lymphocytes are found interspersed between keratino‐
cytes throughout the epidermis and in somewhat larger quantities in the dermis. In fact, a
significant fraction of dermal ‘‘mononuclear’’ inflammatory cells seen in routine sections is
due to T cell infiltration. T cell subsets are not uniformly distributed in psoriasis lesions. Epi‐
dermal T cells are chiefly CD8+ T cells, with a significant fraction of these cells specialized
for homing to epithelia through expression of the integrin aeb7, which binds E-cadherin as‐
sociated with desmosomes. Dermal T lymphocytes are a mixture of CD4+ and CD8+ cells,
with a CD4+ predominance similar to that seen in peripheral blood. Most T cells in skin le‐
sions are memory cells that express cutaneous lymphocyte antigen (CLA), the skin addres‐
sin. [27] In contrast, only, 10% of circulating T lymphocytes are CLA+. Hence, CLA+ T cells
are impressively and selectively targeted to inflammatory psoriasis lesions [29].
Although a case report in 1979 suggested that cyclosporin A could clear psoriasis, this dis‐
ease was generally considered to be a primary disorder of keratinocytes in the early eighties.
A direct role of T cells in the pathogenesis of psoriasis was first suggested in 1983, and it
was independently demonstrated that the eruption of psoriatic skin lesions coincided with
epidermal influx of dendritic cells (DCs) and T cells and that resolution of psoriatic lesions
during phototherapy was preceded by depletion of T cells, especially from the epidermis.
The efficacy of cyclosporin A in psoriasis was subsequently confirmed in two independent
studies and trials with anti-CD4 monoclonal antibodies and an interleukin-2-toxin conjugate
further supported that psoriasis is a T cell-mediated disease. These T cell-specific treatments
resulted in the normalization of the keratinocyte proliferation and epidermal thickening.
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The key role of T cells in psoriasis was conclusively demonstrated in 1996 when psoriatic
lesions were induced by injecting autologous T cells into uninvolved psoriatic skin trans‐
planted to SCID mice. It was further shown in this model that psoriatic lesions could be in‐
duced by injecting purified CD4+ T cells into uninvolved psoriatic skin but no changes were
seen when purified CD8+ T cells were injected. Although CD4+ T cells therefore seem to be
essential for initiating psoriatic lesions, CD8+ T cells may also have an important role in the
pathogenic process as uninvolved psoriatic epidermis contains an increased number of
CD8+ T cells that may be able to proliferate locally with the help of IL-7 and IL-15, cytokines
that are produced by keratinocytes [30].
11. Pathogenesis of vascular changes in psoriasis
Vascular endothelial  growth factor (VEGF) has been implicated in the pathologic angio‐
genesis observed in psoriasis and other chronic inflammatory skin diseases that are char‐
acterized  by  enhanced  expression  of  VEGF  by  epidermal  keratinocytes  and  of  VEGF
receptors by tortuous microvessels in the upper dermis. In addition, the number of mast
cells in the upper dermis was significantly increased in transgenic skin. Highly increased
leukocyte rolling and adhesion in postcapillary skin venules that were both inhibited af‐
ter injection of blocking antibodies against E- and P-selectin were also seen in experimen‐
tal  studies.  It  was also revealed that VEGF is a growth factor specific for blood vessels,
but not lymphatic vessels, and that chronic orthotopic overexpression of VEGF in the ep‐
idermis is sufficient to induce cardinal features of chronic skin inflammation, providing a
molecular link between angiogenesis,  mast cell  accumulation,  and leukocyte recruitment
to sites of inflammation.
As early as in the 70s Braverman had done an electron microscopic study of ultrastruc‐
ture  of  the  capillary  loops  in  the  dermal  papillae  of  psoriatic  lesions.  Normal  dermal
papillary vessels are arterial in nature but in psoriasis these vessels change to have a ve‐
nous capillary structure.  Following 3 weeks of  Goeckerman therapy,  the morphology of
psoriatic capillary loops changed from venous capillaries to arterial capillaries which are
found in the papillae of normal skin. This transformation was observed to begin 48 to 72
hr after the initiation of therapy [31].
Four-fold increase of endothelial microvascular bed is reported in the psoriatic skin but not
in normal skin, thus signifying the importance of angiogenesis in psoriasis. Dermal micro‐
vascular expansion with abnormal orientation and dilatation of capillaries in the biopsies of
the psoriatic skin revealed that the disease was angiogenesis dependent. The keratinocytes
in the psoriatic skin lesions were recognized as a source of pro-angiogenic cytokines which
induce angiogenesis, namely the vascular endothelial growth factor (VEGF). Other com‐
monly recognized cytokines were endothelial cell stimulating angiogenesis factor (ESAF),
tumor necrosis factor-α (TNF-α) and platelet derived growth factors (PDGF) and newly dis‐
covered VEGF-C, NGF and vWFr [32].
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Psoriatic skin is also characterized by microvascular hyperpermeability and angioprolifera‐
tion. The hyperplastic epidermis of psoriatic skin expresses strikingly increased amounts of
vascular permeability factor (VPF; vascular endothelial growth factor), a selective endothe‐
lial cell mitogen that enhances microvascular permeability. Moreover, two VPF receptors,
kdr and flt-1, are overexpressed by papillary dermal microvascular endothelial cells. Trans‐
forming growth factor alpha (TGF-alpha), a cytokine that is also overexpressed in psoriatic
epidermis, induced VPF gene expression by cultured epidermal keratinocytes. VPF secreted
by TGF-alpha-stimulated keratinocytes was bioactive, as demonstrated by its mitogenic ef‐
fect on dermal microvascular endothelial cells in vitro. Together, these findings suggest that
TGF-alpha regulates VPF expression in psoriasis by an autocrine mechanism, leading to vas‐
cular hyperpermeability and angiogenesis [33].
12. Role of keratinocytes in the pathogenesis of psoriasis
As mentioned earlier, it is the epidermal hyperplasia along with abnormal maturation of
keratinocytes that leads to the development of the thick scaly plaques that are so characteris‐
tic of psoriasis. Gottlieb AB suggested that the epidermal changes and the inflammatory in‐
filtrate composed of T cells with interspersed neutrophils may be linked together by the
cytokines produced by both keratinocytes and leukocytes. Her proposal was based partly,
on the fact that epidermal acanthosis and keratinocyte mitoses were often seen in delayed-
type hypersensitivity reactions and after the intradermal injection of gamma interferon.
Gamma interferon and its induced proteins have been demonstrated in active psoriatic pla‐
ques. Increased levels of the keratinocyte autocrine cytokines, transforming growth factor
(TGF)-alpha and interleukin (IL)-6, have been detected in active plaques. The apparent over‐
expression of IL-6 in hyperplastic psoriatic tissue may explain features of psoriasis that link
keratinocyte proliferation with immune activation and tissue inflammation. Both IL-6 and
gamma interferon increased TGF-alpha expression in normal cultured keratinocytes. Cyto‐
kines produced during immune activation and other inflammatory processes may lead to
epidermal hyperplasia. This indicated that keratinocytes have an important role to play in
the pathogenesis of the disease [34].
The French worker Julien D also suggested most recently that since psoriasis is a polymor‐
phous disease and is an example of an interaction of susceptibility genes, immunological
mechanisms and modifying factors, it is unwise to look at the disease as either as an exclu‐
sive disorder of the immune system or in an isolated primitive change of the epithelial or
stromal skin cells. According to the author, it is more likely that various combinations of se‐
lective abnormalities of these two compartments give rise to the psoriatic phenotype. In‐
deed, if in one hand T-cells are essential in the development of psoriatic plaques, the role of
innate immunity in this process is better recognized, and numerous psoriasis susceptibility
genes are linked to immunity, on the other hand some susceptibility factors related to primi‐
tive abnormalities of keratinocytes and some of the most recent murine models of psoriasis
are based on modifications targeted to the keratinocytes [35].
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In  an  exploration  into  the  biochemical  basis  of  the  psoriatic  pathway,  Grove  T,  found
anomalies in protein expression as the basis for abnormal differentiation and hyperprolif‐
eration of the keratinocytes in psoriatic lesions.  At least six markers of abnormal kerati‐
nocyte differentiation have been found, and all  have implications in the pathogenesis of
the disease. These include aberrations of keratinocyte transglutaminase type I (TGase K),
skin-derived  antileukoproteinase  (SKALP),  migration  inhibitory  factor-related  protein-8
(MRP-8), Involucrin, Filaggrin and keratin expression. Several possible biochemical caus‐
es for the overproduction of the keratinocytes have been found in psoriatic skin: epider‐
mal  growth  factor  (EGF),  bone  morphogenetic  protein-6  (BMP-6),  transforming  growth
factor-alpha (TGF-a),  ornithine decarboxylase,  activating protein (AP1) and mitogen-acti‐
vated protein kinase (MAPK) [36].
13. Cytokines and chemokines in the pathogenesis of psoriasis
Once T cells are activated following possible encounters with unknown antigen, they re‐
lease  cytokines  specific  for  T-helper  type  1  (TH1)  cells.  These  cells  in  turn,  play  a  key
role in the pathogenesis of psoriasis. Both activated CD4+ and CD8+ T lymphocytes pro‐
duce  TH1 cytokines.  Key  TH1-type  cytokines  involved  in  the  pathogenesis  of  psoriasis
are IFN-y,  interleukin (IL)-2,  and TNF-a.  IL-2 stimulates T-lymphocyte growth, and IL-2
treatment is associated with psoriasis flares. IFN-y may inhibit apoptosis of keratinocytes
by stimulating expression of  the anti-apoptotic  protein Bcl-x in these cells.  This  may be
the key to the keratinocyte hyperplasia in psoriatic lesions along with TNF-α. The latter
is  also  thought  to  be  responsible  for  setting  forth  the  release  of  proinflammatory  cyto‐
kines  from T lymphocytes  and macrophages,  of  chemokines  from macrophages,  and of
adhesion molecules from vascular endothelial cells. In addition, TH1 cytokines cause the
release of cytokines from other cells [37]. Although the evidence for the Th1 profile was
strong,  IFN-γ,  TNF-α,  and  IL-12,  but  not  IL-4,  IL-5,  or  IL-10,  were  also  demonstrated
within  psoriatic  lesions  at  the  mRNA  and  protein  levels.  This  suggested  synergy  be‐
tween  IFN-γ  and  TNF-α  with  regard  to  production  of  adhesion  molecules  such  as
ICAM-1,  and chemotactic  polypeptides  such as  IL-8  or  monocyte  chemotactic  activating
factor-1 (MCAF-1) [38]. Chemokines and chemokine receptors were also discovered to be
involved  in  the  immunopathogenesis  of  psoriasis.  These  include  among  many  others,
CCL17,  MIG,  CXCL9  and  RANTES  (CCL5).  In  addition,  nitric  oxide  is  present,  which
may  contribute  to  an  angiogenic  tissue  reaction,  accompanied  by  many  growth  factors
present at  elevated levels  within psoriatic  plaques,  including TGF-α,  IGF-1,  keratinocyte
growth factor (KGF), VEGF, nerve growth factor (NGF), amphiregulin, and IL-20 [39].
14. Environmental factors and psoriasis
With evidence of a genetic background but the with the confounding lack of 100% concord‐
ance in monozygotic twin studies and with the eruptions of guttate psoriasis often being
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preceded by a streptococcus pyogenes infection as well as the wealth of studies pointing to
immune-mediated (possibly autoimmune-mediated) inflammation, it is no wonder that a
complex disease like psoriasis has known to be associated with or possibly precipitated by
environmental factors. These environmental trigger factors can be mechanical injury, ultra‐
violet, and chemical injury; various infections; prescription drug use; psychological stress;
smoking; and other factors. The most compelling of these is infection with group A strepto‐
cocci. Streptococcal throat infections frequently precede outbreaks of guttate psoriasis which
can then lead to chronic plaque psoriasis. Furthermore, guttate psoriasis is more common in
individuals with a family history of plaque psoriasis. A recent study of 29 patients from the
UK revealed that all patients with guttate psoriasis carried the HLA-Cw*0602 allele.These
same HLA associations are seen in chronic plaque psoriasis, which may also be aggravated
by infection. Patients with psoriasis may also have different clinical features depending on
whether they are HLA-Cw6 positive or negative. Besides possibly having a lower age of on‐
set, HLA-Cw*0602 positive patients are reported to have more extensive plaques on their
arms, legs, and trunk, more severe disease, higher incidence of the Koebner phenomenon,
reported more often that their psoriasis got worse during or after throat infections, and more
often had a favorable response to sunlight. In contrast, dystrophic nail changes and psoriatic
arthritis are reported to be more common in Cw6-negative patients [40].
Deluvio et al (2006) explored the relationship of Streptococcus pyogenes angina with psoria‐
sis. Using TCR analysis, they tried to identify a link between streptococcal angina and the T
cell-mediated autoimmune response in psoriasis. They compared the TCR usage of psoriatic
skin lesions, blood, tonsils, and tonsillar T cells fractionated according to the expression of
the skin address in "cutaneous lymphocyte-associated Ag" (CLA). They found that clones of
T cells in the throat of at least one of their three streptococcal patients were similar to the T
cell clones in the psoriatic lesion. Because, after tonsillectomy psoriasis cleared in all three of
their patients they concluded that T cells may connect psoriatic inflammation to streptococ‐
cal angina. They suggest that the chronic streptococcal immune stimulus within the tonsils
could act as a source for pathogenic T cells in poststreptococcal disorders, and they may
help to explain why eliminating this source with tonsillectomy may improve streptococcal-
induced sequelae [41].
15. Koebner phenomenon
The Koebner phenomenon is defined as 'the development of psoriasis at sites of traumatized
skin'. The 'all-or-none principle' means that, if psoriasis occurs in one area of injury, all in‐
jured areas develop psoriasis or vice versa. This principle was however, disproved by Ka‐
layciyan et al who did a study on sixty-two patients with psoriasis. The medial aspects of
both forearms, devoid of lesions, were pricked using two sets of five 30-gauge needles at an
angle of 30 degrees, with 2-cm intervals. On days 14 and 28, the patients' forearms were
checked for the presence of a typical psoriatic plaque of white scales on an erythematous
papule. On day 28, 45 patients (72.5%) had a negative Koebner response in all prick sites
whereas 1 patient (1.6%) had psoriatic papules in 10 out of 10 prick sites. The rest of the pa‐
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tients (n = 16, 25.8%) had between 1 and 9 papules in number. This suggests that the ‘all or
none’ principle does not work in psoriatic patients with Koebner phenomenon [42].
16. Conclusion
For decades, the ongoing controversy on the molecular nature, choreography and hierarchy
of these complex interactions e.g., between epidermal keratinocytes, T cells, neutrophils, en‐
dothelial cells and sensory nerves has served as a driving force propelling investigative der‐
matology to ever-new horizons. There is no question that advances in understanding the
cellular immunology and biology of psoriasis, when coupled with the biotechnology revolu‐
tion and rapid advances derived from human genetic studies of autoimmunity, have en‐
hanced insights into the cause and treatment of psoriasis.
The disease starts with the activation of T lymphocyte with an unknown antigen or gene
product.  T  cell  activation depends on its  binding with APC (antigen presenting cell).  T
cells express the cell receptor known as TCR (T cell receptor), which recognizes the pep‐
tide being presented by the APC in the grove of MHC complex. The antigen stimulated
activation  leads  to  the  conversion  of  naive  T-cells  into  an  antigen  specific  cell,  which
may  develop  into  a  memory  cell  that  circulate  in  the  body.  After  the  activation  of  T
cells,  a  cascade  of  cytokines  viz.  GMCSF  (granulocyte  macrophage  colony  stimulating
factor),  EGF,  IL-1,  IL-6,  IL-8,  IL-12,  IL-17,  IL-23,  Fractalkine,  TNF-α etc.  are  secreted by
the activated T Cells.  Due to effect of these cytokines there is keratinocyte proliferation,
neutrophil  migration,  potentiation of  Th-1  type response,  angiogenesis,  up-regulation of
adhesion molecule and epidermal hyperplasia [43].
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